Riskpilot← Back to searchSign inGet full accessSKIVE & HELSTED A/S
A/SActiveCVR 28964447Kong Haralds Vej 4Activities of holding companies · NACE 6421Est. 2005— employees
Revenue 2025
DKK 3K
-116% vs 2024
EBITDA margin
100.0%
+116% vs 2024
Equity ratio
-170050.9%
Financial strength
Net profit 2025
DKK 261K
+186% vs 2024
| Revenue | DKK 3K | -116% |
| EBITDA | DKK 3K | +116% |
| Net profit | DKK 261K | +186% |
| Total assets | DKK 509 | -88% |
| Equity | DKK -866K | +23% |
| Employees | — | — |
Legal name
SKIVE & HELSTED A/S
CVR number
28964447
Legal form
Aktieselskab
NACE code
6421 · Activities of holding companies
Founded
8. august 2005
Share capital
DKK 500.000
Employees
—
VAT registered
No
Audit selected
Yes
Last report
2025-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er investerings-, finansierings- og handelsvirksomhed samt ejendomsadministration.
Address
Kong Haralds Vej 4
Phone
+4553695900
Email
jeanne@acupharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -16 | -17 | -18 | -18 | 3 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -16 | -17 | -18 | -18 | 3 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -16 | -17 | -18 | -18 | 3 |
| Net financials | 11 | -443 | 153 | -286 | 260 |
| Profit before tax | -6 | -460 | 135 | -304 | 263 |
| Tax | -4 | 13 | -0 | -0 | 2 |
| Net profit | -2 | -474 | 135 | -304 | 261 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 172 | 6 | 5 | 4 | 1 |
| Equity | -484 | -957 | -822 | -1.126 | -866 |
| Long-term debt | 0 | 0 | 0 | 0 | 522 |
| Short-term debt | 655 | 672 | 690 | 733 | 234 |
| Total debt | 655 | 672 | 690 | 733 | 757 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20212025
Equity ratio
-170050.9%
This company
38.2%
Market median
-445259% vs market
20212025
Return on equity
26052100.0%
This company
18.4%
Market median
+141587400% vs market
20212025
Net profit margin
8801.4%
This company
8.1%
Market median
+108559% vs market
20212025
Asset turnover
5.82×
This company
1.12×
Market median
+420% vs market
20212025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CU Chief Executive Officer | Chief Executive Officer | 2013 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2005 | |
| Former (2) | ||
| Board of Directors | 2005 – 2013 | |
| Board of Directors | 2005 – 2009 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2015 | |
| Individual | 50–66.65% | 50–66.65% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SKIVE & HELSTED A/S 
ACUPHARMA ApSBoard members of SKIVE & HELSTED A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christina Uekermann Skive | Chief Executive Officer | 0 companies |
| Thomas Fog Helsted | Board of Directors | 0 companies |
| Søren Skive | Board of Directors | 0 companies |
| Christian Bendik Elmer | Board of Directors | 0 companies |